Cargando…
The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold
KEY CLINICAL MESSAGE: There is no effective treatment that reduces both the severity and duration of a common cold episode. SJP − 002 (naproxen and fexofenadine) reduced symptom severity by two‐third, and the duration of the common cold episode approximately by half. ABSTRACT: The common cold is one...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359448/ https://www.ncbi.nlm.nih.gov/pubmed/37484744 http://dx.doi.org/10.1002/ccr3.7682 |
_version_ | 1785075884465586176 |
---|---|
author | Išerić, Emina Dahl, Thomas A. Scholey, Andrew Iversen, Jacqueline M. Verster, Joris C. |
author_facet | Išerić, Emina Dahl, Thomas A. Scholey, Andrew Iversen, Jacqueline M. Verster, Joris C. |
author_sort | Išerić, Emina |
collection | PubMed |
description | KEY CLINICAL MESSAGE: There is no effective treatment that reduces both the severity and duration of a common cold episode. SJP − 002 (naproxen and fexofenadine) reduced symptom severity by two‐third, and the duration of the common cold episode approximately by half. ABSTRACT: The common cold is one of the most frequently experienced immune‐related complaints. At present, available treatments have limited efficacy in inhibiting symptoms associated with upper respiratory tract infection, nor do they significantly shorten the duration of common cold episodes. Four case reports are presented of individuals with a common cold. Three of them self‐administered the combination of naproxen and fexofenadine (SJP − 002). Results of one individual were compared to her spouse, who did not take SJP − 002 to treat common cold, while two other individuals took SJP − 002 and compared symptom severity with another common cold episode they experienced previously without taking SJP − 002. SJP − 002 reduced the severity of symptoms associated with upper respiratory tract infection by two‐third and reduced the duration of the common cold episode approximately by half. In conclusion, SJP − 002 reduced the severity and duration of common cold episodes. These findings warrant further investigation of SJP − 002 in double‐blind, placebo‐controlled clinical trials. |
format | Online Article Text |
id | pubmed-10359448 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103594482023-07-22 The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold Išerić, Emina Dahl, Thomas A. Scholey, Andrew Iversen, Jacqueline M. Verster, Joris C. Clin Case Rep Case Report KEY CLINICAL MESSAGE: There is no effective treatment that reduces both the severity and duration of a common cold episode. SJP − 002 (naproxen and fexofenadine) reduced symptom severity by two‐third, and the duration of the common cold episode approximately by half. ABSTRACT: The common cold is one of the most frequently experienced immune‐related complaints. At present, available treatments have limited efficacy in inhibiting symptoms associated with upper respiratory tract infection, nor do they significantly shorten the duration of common cold episodes. Four case reports are presented of individuals with a common cold. Three of them self‐administered the combination of naproxen and fexofenadine (SJP − 002). Results of one individual were compared to her spouse, who did not take SJP − 002 to treat common cold, while two other individuals took SJP − 002 and compared symptom severity with another common cold episode they experienced previously without taking SJP − 002. SJP − 002 reduced the severity of symptoms associated with upper respiratory tract infection by two‐third and reduced the duration of the common cold episode approximately by half. In conclusion, SJP − 002 reduced the severity and duration of common cold episodes. These findings warrant further investigation of SJP − 002 in double‐blind, placebo‐controlled clinical trials. John Wiley and Sons Inc. 2023-07-20 /pmc/articles/PMC10359448/ /pubmed/37484744 http://dx.doi.org/10.1002/ccr3.7682 Text en © 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Išerić, Emina Dahl, Thomas A. Scholey, Andrew Iversen, Jacqueline M. Verster, Joris C. The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold |
title | The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold |
title_full | The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold |
title_fullStr | The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold |
title_full_unstemmed | The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold |
title_short | The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold |
title_sort | efficacy of a combination of naproxen and fexofenadine (sjp − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: four case reports of individuals with common cold |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359448/ https://www.ncbi.nlm.nih.gov/pubmed/37484744 http://dx.doi.org/10.1002/ccr3.7682 |
work_keys_str_mv | AT isericemina theefficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold AT dahlthomasa theefficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold AT scholeyandrew theefficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold AT iversenjacquelinem theefficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold AT versterjorisc theefficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold AT isericemina efficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold AT dahlthomasa efficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold AT scholeyandrew efficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold AT iversenjacquelinem efficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold AT versterjorisc efficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold |